A phase I study of tipifarnib in combination with imatinib mesylate (IM) for patients (Pts) with chronic myeloid leukemia (CML) in chronic phase (CP) who failed IM therapy.

被引：0
|
作者：
Cortes, J
Garcia-Manero, G
O'Brien, S
Hernandez, I
Rackoff, W
Faderl, S
Thomas, D
Ferrajoli, A
Talpaz, M
Kantarjian, H
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Johnson & Johnson Pharmaceut Res & Dev, LLC, Titusville, NJ USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1011
引用
收藏
页码：289A / 289A
页数：1
相关论文
共 50 条
  • [21] Phase I study of lonafarnib (SCH66336) in combination with imatinib for patients (pts) with chronic myeloid leukemia (CML) after failure to imatinib.
    Cortes, J
    O'Brien, S
    Verstovsek, S
    Daley, G
    Koller, C
    Ferrajoli, A
    Pate, O
    Faderl, S
    Ravandi-Kashani, F
    Talpaz, M
    Zhu, YL
    Statkevich, P
    Sugrue, M
    Kantarjian, H
    BLOOD, 2004, 104 (11) : 288A - 288A
  • [22] Clinical significance of molecular monitoring in chronic myeloid leukemia (CML) in chronic phase (CP) with imatinib therapy
    Cortes, J
    Talpaz, M
    O'Brien, S
    Jones, D
    Luthra, R
    Garcia-Manero, G
    Giles, F
    Shan, J
    Verstovsek, S
    Rios, MB
    Kantarjian, H
    BLOOD, 2004, 104 (11) : 81A - 81A
  • [23] Phase I study of a imatinib and tipifarnib (Zarnestral™, R115777) in patients with chronic myeloid leukemia in chronic phase refractory to imatinib.
    Cortes, J
    Garcia-Manero, G
    O'Brien, S
    Hernandez, I
    Rackoff, W
    Faderl, S
    Thomas, D
    Talpaz, M
    Kantarjian, H
    BLOOD, 2003, 102 (11) : 909A - 909A
  • [24] Studying the Impact of Imatinib Mesylate (IM) Adherence in Chronic Myeloid Leukemia (CML) patients' Responses in the State of Qatar
    Al-Dewik, Nader I.
    Morsi, Hisham
    Ghasoub, Rola
    Yassin, Mohamed A.
    BLOOD, 2014, 124 (21)
  • [25] Tipifarnib (ZARNESTRA™) and imatinib (GLEEVEC™) combination therapy in patients with advanced chronic myelogenous leukemia (CML):: Preliminary results of a phase I study.
    Gotlib, J
    Mauro, M
    O'Dwyer, ME
    Fechter, L
    Dugan, K
    Kuyl, J
    Yekrang, A
    Mori, M
    Rackoff, W
    Coutre, S
    Druker, B
    Greenberg, PL
    BLOOD, 2003, 102 (11) : 909A - 910A
  • [26] Subcutaneous (SC) homoharringtonine (HHT) for patients (pts) with chronic myelogenous leukemia (CML) in chronic phase (CP) after imatinib mesylate failure.
    Quintas-Cardama, A
    Cortes, J
    Verstovsek, S
    Laddie, N
    Estrov, Z
    Kantarjian, H
    BLOOD, 2005, 106 (11) : 290B - 290B
  • [27] Imatinib dose escalation is effective in patients with chronic myeloid leukemia in chronic phase (CML-CP)
    Kantarjian, Hagop M.
    Druker, Brian J.
    Guilhot, Francois
    Cortes, Jorge
    O'Brien, Stephen G.
    Krahnke, Tillmann
    Larson, Richard A.
    BLOOD, 2007, 110 (11) : 317A - 317A
  • [28] EPIC: A PHASE 3 TRIAL OF PONATINIB VS IMATINIB IN PATIENTS (PTS) WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CP-CML)
    Chuah, C.
    Guerci-Bresler, A.
    Rosti, G.
    Simpson, D.
    Lustgarten, S.
    Trede, N.
    Rivera, V. M.
    Clackson, T.
    Haluska, F. G.
    Baccarani, M.
    Cortes, J. E.
    Guilhot, F.
    Hochhaus, A.
    Hughes, T.
    Kantarjian, H.
    Shah, N. P.
    Talpaz, M.
    Deininger, M. W.
    Lipton, J. H.
    HAEMATOLOGICA, 2014, 99 : 238 - 238
  • [29] Medical costs associated with imatinib (IM) non-compliance in chronic myeloid leukemia (CML) patients (pts)
    Wu, E. Q.
    Feng, W.
    Johnson, S.
    Beaulieu, N.
    Cremieux, P.
    Cortes, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [30] Long-term bosutinib (BOS) in patients (pt) with chronic phase (CP) chronic myeloid leukemia (CML) after prior imatinib (IM) failure.
    Lipton, Jeffrey Howard
    Cortes, Jorge E.
    Khoury, Hanna Jean
    Kantarjian, Hagop M.
    Kim, Dong-Wook
    Schafhausen, Philippe
    Zeremski, Mirjana
    Bardy-Bouxin, Nathalie
    Shapiro, Mark
    Leip, Eric
    Gambacorti-Passerini, Carlo
    Bruemmendorf, Tim H.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345